Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Palisade Capital Management LP

Palisade Capital Management LP lifted its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 34.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,286,931 shares of the biotechnology company's stock after acquiring an additional 1,360,542 shares during the period. Palisade Capital Management LP owned 3.47% of Heron Therapeutics worth $11,631,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nicolet Advisory Services LLC purchased a new stake in Heron Therapeutics in the 4th quarter worth about $25,000. RFP Financial Group LLC bought a new position in shares of Heron Therapeutics during the first quarter valued at approximately $26,000. Argent Advisors Inc. acquired a new stake in Heron Therapeutics in the fourth quarter valued at approximately $31,000. Focus Partners Wealth acquired a new stake in Heron Therapeutics in the fourth quarter valued at approximately $31,000. Finally, State of Wyoming boosted its stake in Heron Therapeutics by 573.5% in the fourth quarter. State of Wyoming now owns 29,736 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 25,321 shares in the last quarter. Institutional investors own 80.01% of the company's stock.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX traded up $0.02 during midday trading on Friday, hitting $2.17. The company had a trading volume of 823,589 shares, compared to its average volume of 2,184,221. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.73. The stock has a market cap of $330.29 million, a price-to-earnings ratio of -36.08 and a beta of 1.18. The business's 50-day simple moving average is $2.06 and its 200-day simple moving average is $1.96.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. As a group, sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. HC Wainwright started coverage on shares of Heron Therapeutics in a report on Monday, June 9th. They issued a "buy" rating and a $6.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 6th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.